Results 181 to 190 of about 226,521 (286)

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

open access: yesAddiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne   +9 more
wiley   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

open access: yesAddiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Exploring the Link: Marijuana Use Patterns and Their Impact on Coronary Heart Disease Risk. [PDF]

open access: yesClin Cardiol
Wei T   +8 more
europepmc   +1 more source

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

open access: yesAddiction, EarlyView.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring   +8 more
wiley   +1 more source

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling

open access: yes
Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

open access: yesAddiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

open access: yesAddiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark   +8 more
wiley   +1 more source

A meta‐analysis of sexual orientation inequities in substance use among youth

open access: yesAddiction, EarlyView.
Abstract Background and Aims Sexual minority youth report significantly higher rates of substance use than heterosexual youth, yet a comprehensive and systematic evaluation and synthesis of the magnitude of this inequity has not been conducted. The purpose of this study was to conduct a meta‐analysis to assess the magnitude of overall inequities in ...
Ethan H. Mereish   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy